Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies Authors: Qinyu Ni, Lixin Rui Published: 2026 ABSTRACT Bruton tyrosine kinase inhibitors (BTKis) have markedly improved the treatment landscape for B cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and Waldenström’s macroglobulinemia, since the introduction of the first-in-class BTKi, ibrutinib, a decade ago. Despite their clinical success, the emergence of resistance to BTKis poses a significant therapeutic challenge. The mechanisms of resistance are multifactorial and include genetic mutations, activation of alternative oncogenic signaling pathways, dysregulated protein expression, alterations in the tumor microenvironment, and metabolic reprogramming. To address these challenges, several therapeutic strategies are under active investigation, such as next-generation noncovalent BTKis, BTK-targeting proteolysis approaches (e.g., PROTACs), and combination therapies (e.g., with bispecific antibodies or chimeric antigen receptor T [CAR T] cells) designed to bypass or overcome resistance pathways. This review provides a comprehensive overview of the mechanisms driving BTKi resistance and discusses current preclinical and clinical strategies aimed at improving therapeutic outcomes in B cell malignancies. Introduction B cell malignancies represent the most common hematologic malignancies and account for approximately 95% of all cases of non-Hodgkin lymphoma (NHL), leading to over 20,000 deaths annually in the United States.1 The principal NHL subtypes include diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM).2 Bruton tyrosine kinase (BTK) is essential for B cell receptor (BCR) signaling, facilitating the proliferation, survival, and migration of normal B cells within the humoral immune response. Dysregulation of BTK signaling, resulting from various genetic and non-genetic mechanisms, has been implicated in the pathogenesis of multiple B cell lymphomas. Consequently, BTK has become a prominent therapeutic target, and the development of BTK inhibitors (BTKis) marks a significant advancement in the management of B cell malignancies.3 Over the past decade, ibrutinib emerged as the first-in-class BTKi, initiating a shift toward chemotherapy-free regimens. Subsequently, for the purposes of this review, we define second-generation BTKis as covalent agents with improved selectivity, including acalabrutinib, zanubrutinib, tirabrutinib, and orelabrutinib, and third-generation BTKis as noncovalent (reversible) agents, including pirtobrutinib and nemtabrutinib.4,5 Nonetheless, the emergence of acquired resistance, mediated by diverse mechanisms, remains a significant obstacle in optimizing therapeutic outcomes. This review provides a comprehensive overview of the role of BTKis in treating B cell malignancies, summarizes clinical efficacy across lymphoma subtypes, and examines their impact on patient outcomes. It also addresses the main challenges and limitations associated with BTK inhibition, including resistance, adverse effects, and strategies to overcome these barriers. By integrating recent research findings and clinical experience, this review elucidates the current landscape of BTKi therapy and outlines potential future directions in hematologic oncology. BTK signaling in regulation of B cell activation and proliferation BCR signaling and BTK activation BTK is a non-receptor protein-tyrosine kinase encoded by a gene on the human X chromosome at position Xq22.1.6 BTK is required for all stages of B cell development, from immature cells in the bone marrow to mature B cells at various stages of differentiation (Figure 1).7 The protein is named after Ogden Bruton, who first identified the defective protein in X-linked agammaglobulinemia, a genetic immunodeficiency characterized by the absence of mature B cells.8 BTK is a 77-kDa protein composed of 659 amino acids and contains five distinct protein interaction domains: PH, TH, SH3, SH2, and the tyrosine kinase domain.9 While BTK is critical for B cell development, it also functions in other hematopoietic cells, including myeloid cells, mast cells, and platelets. Within the cell, BTK is primarily localized in the cytoplasm and translocates to the plasma membrane upon activation.10 As a central component of BCR signaling, BTK also participates in additional signaling pathways such as TLR signaling, Fc receptor signaling, NF-κB and NFAT pathways, and the MAPK cascade.7Figure 1The BCR/BTK signaling pathwayBTK functions as a key signaling node within the BCR pathway, activating multiple interconnected pathways that are essential for B cell survival, proliferation, and differentiation. These signaling branches are frequently dysregulated or exploited in B cell lymphomas. A comprehensive understanding of BTK-dependent pathway integration is crucial for identifying novel therapeutic targets and addressing drug resistance in B cell malignancies. See the main text for more details. The BCR/BTK signaling pathway BTK functions as a key signaling node within the BCR pathway, activating multiple interconnected pathways that are essential for B cell survival, proliferation, and differentiation. These signaling branches are frequently dysregulated or exploited in B cell lymphomas. A comprehensive understanding of BTK-dependent pathway integration is crucial for identifying novel therapeutic targets and addressing drug resistance in B cell malignancies. See the main text for more details. BCR complex is a monomeric form of an antibody that consists of two main components: membrane-bound immunoglobulin (mIg) and signaling subunits (Igα and Igβ).11 CD79A (Igα) and CD79B (Igβ) are two transmembrane proteins covalently linked by a disulfide bond to form a heterodimer and are non-covalently associated with the mIg.12 Their intracellular tails contain immunoreceptor tyrosine-based activation motifs (ITAMs), which are essential for initiating downstream signaling upon antigen binding.12 Tonic BCR signaling and antigen-induced BCR signaling represent two distinct modes of BCR activation (Figure 1).13 In tonic signaling, BCRs primarily exist as monomers or dimers distributed across the plasma membrane.14 This configuration is marked by spontaneous, low-level receptor clustering that sustains basal phosphatidylinositol 3-kinase (PI3K) activity and supports cell survival without triggering full activation or proliferation.15 In contrast, antigen-induced BCR signaling is initiated when an antigen binds to the variable regions of the mIg via non-covalent interactions. This event induces conformational changes in the BCR, leading to the assembly of large oligomeric clusters.14 The resulting clustering brings the cytoplasmic tails of Igα/Igβ heterodimers into close proximity, facilitating phosphorylation of tyrosine residues within their ITAMs by the Src family kinase LYN. These phosphorylated residues become docking sites for SYK kinase, which binds via its tandem SH2 domains.16 This interaction induces a conformational change in SYK, aligning its catalytic domain for activation. SYK is further phosphorylated by LYN and undergoes autophosphorylation, resulting in full activation.17 Activated SYK phosphorylates multiple tyrosine residues on the B cell linker protein (BLNK), establishing a scaffold for additional signaling molecules and initiating a complex signaling cascade. Activated SYK phosphorylates BLNK, a scaffold protein that recruits key signaling molecules such as BTK, PI3K, and phospholipase Cγ2 (PLCγ2).3 BTK is recruited to the membrane through its pleckstrin homology (PH) domain, which binds to phosphatidylinositol 3,4,5-trisphosphate (PIP3), thereby localizing it near the BLNK complex.18 Activated SYK and LYN phosphorylate tyrosine residues in the cytoplasmic tail of CD19, a BCR co-receptor.18 Phosphorylated CD19 provides docking sites for PI3K.19 The p85 regulatory subunit of PI3K, which contains SH2 domains, binds to these phosphorylated tyrosines. B cell adaptor for PI3K (BCAP), phosphorylated by SYK, serves as an additional docking site for PI3K. This interaction relieves autoinhibition of the p85-p110 complex, bringing the p110 catalytic subunit of PI3K into proximity with the membrane, where its substrate, phosphatidylinositol 4,5-bisphosphate (PIP2), is located. PI3K then converts PIP2 into PIP3 at the plasma membrane. The PH domain of BTK has a high affinity for PIP3, facilitating its recruitment to the inner leaflet of the plasma membrane. BTK also recruits phosphatidylinositol-4-phosphate 5-kinase (PIP5K), which generates PIP2 as a substrate for both PI3K and PLCγ2. At the membrane, BTK is phosphorylated on Y551 in its kinase domain by LYN. This phosphorylation activates BTK, allowing it to undergo autophosphorylation at Y223 in the SH3 domain.3 PLCγ2 contains two SH2 domains in its regulatory region, which enable it to bind to specific phosphorylated tyrosines on BLNK.20 Upon binding to these sites in the cytosol, PLCγ2 interacts with PIP3 through the weak affinity of its PH domain, which facilitates its localization to the membrane. BTK, in close proximity, phosphorylates PLCγ2 on tyrosine residues Y753 and Y759, rendering it catalytically active. Activated PLCγ2 then hydrolyzes PIP2 into inositol trisphosphate (IP3) and diacylglycerol (DAG).3 IP3-mediated calcium signaling IP3 binds to the IP3 receptor (IP3R) on the endoplasmic reticulum membrane, which has a high affinity for IP3.21 This binding induces a conformational change in IP3R, resulting in the opening of the calcium channel. Calcium ions (Ca2+) stored in the endoplasmic reticulum are released into the cytosol, causing a rapid increase in intracellular calcium concentration and regulating calcium-dependent signaling pathways, including the calcineurin (CaN)/NFAT pathway. Cytosolic calcium binds to the calcium sensor protein calmodulin and activates CaN by displacing its autoinhibitory domain. CaN dephosphorylates NFAT, enabling its activation and nuclear translocation. Additionally, calcium acts synergistically with DAG to activate the conventional PKC isoforms such as PKCβ.22 DAG-mediated PKCβ/RasGRP activation DAG, in conjunction with calcium ions (Ca2+), activates PKCβ (Figure 1).18 DAG binds to the C1 domain of PKCβ, anchoring PKCβ to the membrane, while calcium binds the C2 domain, stabilizing this interaction. This dual binding relieves autoinhibitory interactions within PKCβ, enabling it to phosphorylate its substrates. In parallel, DAG also directly binds and activates RasGRP (Ras guanine nucleotide-releasing protein), which catalyzes the exchange of GDP for GTP on Ras.23 Together with the phosphorylation by PKCβ, DAG-activated RasGRP functions as a Ras guanine nucleotide exchange factor that links BCR signaling to the classical RAS-RAF-MEK-ERK MAPK cascade. Ras-GTP recruits RAF, such as c-Raf, to the plasma membrane, initiating downstream signaling.24 Activated RAF phosphorylates and activates MEK (MAPK/ERK kinase), which in turn phosphorylates ERK (extracellular signal-regulated kinase). Phosphorylated ERK becomes fully active, dissociates from MEK, and translocates to the nucleus, where it phosphorylates and activates transcription factors, including Elk-1and and MYC (c-MYC).25 In addition to ERK1/2, BCR stimulation also engages other MAPK modules including JNK and p38 through small GTPases and mitogen-activated protein kinase kinase kinases (MAP3Ks). Transcriptional factors regulated by those modules are AP-1 (Activator Protein-1),26 CREB (cAMP response element-binding protein),27 ATF-2 (activating transcription factor 2), and MEF2 (myocyte enhancer factor 2), which are associated with stress responses.28,29 PKCβ phosphorylates CARMA1 (also known as CARD11 and BIMP1), which then undergoes a conformational change that enables the formation of the CBM complex with Bcl10 and MALT1 (CBM refers to CARMA1-Bcl10-MALT1).28 The CBM complex functions as a signaling hub to activate the IKK complex. MALT1 recruits and activates E3 ubiquitin ligases such as TRAF6 (TNF receptor-associated factor 6). TRAF6 catalyzes K63-linked polyubiquitination of NEMO (IKKγ), the regulatory subunit of the IKK complex. Polyubiquitinated NEMO recruits and activates IKKβ through phosphorylation. Activated IKKβ phosphorylates IkBα at serine residues Ser32 and Ser36, marking IkBα for ubiquitination and subsequent degradation by the proteasome. Degradation of IκBα releases NF-κB (a RelA/p50 heterodimer), which then translocates to the nucleus and binds specific DNA sequences to activate the transcription of target genes. The NF-κB pathway is essential for B cell development, proliferation, antibody production, and survival.30 Downstream of the BLNK-PI3K-CD19 axis described above, the PI3K generates PIP3, which recruits AKT to the membrane.31 AKT is activated through sequential phosphorylation and subsequently inhibits the TSC1/TSC2 complex, a negative regulator of mTORC1.32 Inhibition of TSC1/TSC2 activates Rheb, a small GTPase that directly activates mTORC1. In energy-rich conditions, PI3K-AKT signaling promotes mTORC1 activity and anabolic growth, whereas during energy stress, activation of the energy sensor AMPK leads to phosphorylation of TSC2 and inhibition of mTORC1, enabling a shift toward catabolic processes.33 Negative regulation of BCR signaling Src Homology 2-containing inositol 5′-phosphatase 1 (SHIP1) contains an SH2 domain that binds to phosphorylated tyrosines on signaling proteins or adaptors (Figure 1).34 PIP3 also recruits SHIP, which dephosphorylates PIP3 back to PIP2, thereby attenuating downstream signaling by reducing PIP3 levels. By decreasing PIP3 availability, SHIP1 indirectly downregulates calcium signaling (via reduced PLCγ2 activation), PKCβ activation and downstream NF-κB signaling, and AKT/mTOR pathway activation, which collectively regulate B cell survival and proliferation.18 Dysregulated signaling pathways in B cell lymphomas Genetic abnormalities within the BCR signaling pathway, along with constitutive BCR activation, drive aberrant cell proliferation and survival, contributing to the development of various B cell lymphoma subtypes.35 The molecular basis of these malignancies is closely associated with subtype-specific genetic alterations, which will be discussed in detail later. Given its essential role in BCR signaling, BTK has become an attractive therapeutic target, leading to the development and clinical implementation of BTKis.36 Development and clinical application of BTKis in B cell malignancies A few years after the identification of BTK, the first rationally designed small-molecule BTKi was developed, demonstrating antitumor activity in leukemic cells in vitro.37 Ibrutinib became the first-in-class BTKi to enter clinical testing. Initially created by scientists at Celera Genomics to study BTK function, ibrutinib was later acquired and renamed PCI-32765 by Pharmacyclics in 2006. It was first studied in preclinical models of rheumatoid arthritis. Its anti-lymphoma activity was reported by Honigberg et al. in a canine model of B cell lymphoma.6 Ibrutinib was subsequently approved for the treatment of MCL, CLL/SLL, WM, and MZL.7 It was also the first targeted therapy to be evaluated for the treatment of DLBCL.38 Ibrutinib was marketed under the brand name Imbruvica. Notably, the accelerated approvals for MCL and MZL were withdrawn in the United States in 2023 (Figure 2).39Figure 2Timeline of BTK inhibitor development and regulatory milestones in B cell malignanciesIbrutinib was the first FDA-approved BTK inhibitor in 2013. Second-generation covalent BTK inhibitors, including acalabrutinib, zanubrutinib, and tirabrutinib, were developed to enhance selectivity and minimize off-target toxicities. Although not FDA approved, tirabrutinib has received regulatory approval in Japan and South Korea and orelabrutinib, in China and Singapore. Pirtobrutinib represents a new class of BTKis designed to overcome resistance associated with C481 mutations. Timeline of BTK inhibitor development and regulatory milestones in B cell malignancies Ibrutinib was the first FDA-approved BTK inhibitor in 2013. Second-generation covalent BTK inhibitors, including acalabrutinib, zanubrutinib, and tirabrutinib, were developed to enhance selectivity and minimize off-target toxicities. Although not FDA approved, tirabrutinib has received regulatory approval in Japan and South Korea and orelabrutinib, in China and Singapore. Pirtobrutinib represents a new class of BTKis designed to overcome resistance associated with C481 mutations. Ibrutinib binds irreversibly to the cysteine 481 (C481) residue in the BTK kinase domain, thereby inhibiting its enzymatic activity.6 Although ibrutinib has demonstrated superior efficacy compared with standard chemoimmunotherapy for B cell malignancies, it also binds to off-target kinases, including members of the Src and TEC kinase families.40,41 This off-target activity contributes to adverse events such as atrial fibrillation, hypertension, bleeding, and hepatotoxicity.42 These toxicities are partly due to the inhibition of other kinases, such as EGFR, ITK, and TEC family members, which are involved in various physiological systems. The combination of off-target toxicity and the emergence of resistance mutations, such as C481S, prompted the development of second-generation BTKis with improved selectivity and reduced side effects. These agents include acalabrutinib, zanubrutinib, tirabrutinib, and orelabrutinib (Figure 2).43 Acalabrutinib (Calquence) was approved by the FDA for MCL in 2017, with its indication later extended to CLL/SLL in 2019.44 In the same year, zanubrutinib (Brukinsa) was approved for MCL based on efficacy results from phase 2 trials (NCT03206970).45 As of 2025, tirabrutinib (Velexbru) and orelabrutinib have received regional approvals.46,47 Tirabrutinib was granted Orphan Drug Designation by the FDA in 2023 for the treatment of primary central nervous system lymphoma (PCNSL), while orelabrutinib received Breakthrough Therapy Designation by the FDA for relapsed/refractory (R/R) MCL in 2021.48 Phase 2 PROSPECT trial (NCT04947319) evaluating tirabrutinib in R/R PCNSL is ongoing (Table 1).71 These second-generation covalent inhibitors continue to target the C481 residue in the BTK active site but possess structurally refined kinase-binding profiles that minimize interactions with other kinases. This enhanced selectivity contributes to a more favorable safety profile.73Table 1Approved and investigational BTK inhibitorsCompoundDisease settingTrial/identifierORRPFSOSFDA approvalIbrutinib (PCI-32765)R/R MCLaPCYC-1104 (NCT01236391)4968% (CR 21%, PR 47%)Median 13.9 months58% at 18 monthsNovember 13, 2013R/R CLL/SLLPCYC-1102 (NCT01105247)5089% (CR 10%)34% at 84 months; median 52 months55% at 84 monthsFebruary 12, 2014Del(17p) CLLRESONATE (NCT01578707)5142.6%88% at 6 months90% at 12 monthsJuly 28, 2014WMNCT016148215290.5%69.1% at 24 months95.2% at 24 monthsJanuary 29, 2015Naive CLL/SLLRESONATE-2 (NCT01722487)5386% after 18.9 months89% at 24 months5498% at 24 monthsMarch 4, 2016R/R MZLaPCYC-1121 (NCT01980628)5558% after 33.1 monthsMedian 15.7 monthsNot reportedJanuary 19, 2017cGVHDPCYC-1129 (NCT02195869)5669% (CR 31%, PR 38%) after 26 monthsNot reportedNot reportedAugust 24, 2017WM (plus rituximab)iNNOVATE (NCT02165397)5790% after 18.1 months86% at 18 months97% at 18 monthsAugust 27, 2018Naive CLL (plus obinutuzumab)iLLUMINATE (NCT02264574)5891% (CR 41%)79% at 30 months86% at 30 monthsJanuary 28, 2019Naive CLL/SLL (plus rituximab)E1912 (NCT02048813)5995.8% (CR 17.2%)89.4% at 36 months98.8% at 36 monthsApril 21, 2020Acalabrutinib (ACP-196)R/R MCLACE-LY-004 (NCT02213926)6081% (CR 40%) after 15.2 months67% at 12 months87% at 12 monthsOctober 31, 2017R/R CLL/SLLASCEND (NCT02970318)6181%Median 16.5 months94% at 12 monthsNovember 21, 2019Naive MCL (plus bendamustine-rituximab)ECHO (NCT02972840)6291% (CR 66.6%) after 49.8 monthsMedian 66.4 monthsNot reachedJanuary 17, 2025Zanubrutinib (BGB-3111)R/R MCLBGB-3111-206 (NCT03206970)6383.7% (CR 77.9%) after 35.3 months47.6% at 36 months; Median 33 months75.8% at 36 monthsNovember 14, 2019WMASPEN (NCT03053440)6421.2% after 44.4 monthsNot reachedNot reachedSeptember 1, 2021R/R MZLMAGNOLIA (NCT03846427)6568.2% after 27.4 months70.9% at 24 months85.9% at 24 monthsSeptember 15, 2021Naive CLL/SLLSEQUOIA (NCT03336333)6697.4% after 31.2 months92% at 24 months96% at 24 monthsJanuary 19, 2023R/R CLLALPINE (NCT03734016)6778.3% after 15 months94.9% at 12 months97.0% at 12 monthsDecember 22, 2023R/R FL (plus obinutuzumab)ROSEWOOD (NCT03332017)6869% (CR 39%) after 20.2 monthsMedian 28 months77% at 24 monthsMarch 7, 2024Pirtobrutinib (LOXO-305)R/R MCLBRUIN (NCT03740529)69,7057.8% (CR 20%)Median 7.4 months59.3 at 18 monthsJanuary 27, 2023CLL/SLL73.3%Median 19.6 months80.5% at 18 monthsDecember 1, 2023Tirabrutinib (ONO-4059)R/R PCNSLPROSPECT (NCT04947319)71–––FDA granted ODD (March 2023)Orelabrutinib (ICP-022)R/R MCLNCT0401420572–––FDA granted BTD (June 2021)cGVHD, chronic graft-versus-host disease; FDA, US Food and Drug Administration; R/R, relapsed/refractory; ORR, overall response rate; CR, complete response; PFS, progression-free survival; OS, overall survival; ODD, Orphan Drug Designation; BTD, Breakthrough Therapy Designation.Patients’ responses and safety profiles are discussed in the text.aWithdrawn in the United States in April 2023.39 Table 1Approved and investigational BTK inhibitorsCompoundDisease settingTrial/identifierORRPFSOSFDA approvalIbrutinib (PCI-32765)R/R MCLaPCYC-1104 (NCT01236391)4968% (CR 21%, PR 47%)Median 13.9 months58% at 18 monthsNovember 13, 2013R/R CLL/SLLPCYC-1102 (NCT01105247)5089% (CR 10%)34% at 84 months; median 52 months55% at 84 monthsFebruary 12, 2014Del(17p) CLLRESONATE (NCT01578707)5142.6%88% at 6 months90% at 12 monthsJuly 28, 2014WMNCT016148215290.5%69.1% at 24 months95.2% at 24 monthsJanuary 29, 2015Naive CLL/SLLRESONATE-2 (NCT01722487)5386% after 18.9 months89% at 24 months5498% at 24 monthsMarch 4, 2016R/R MZLaPCYC-1121 (NCT01980628)5558% after 33.1 monthsMedian 15.7 monthsNot reportedJanuary 19, 2017cGVHDPCYC-1129 (NCT02195869)5669% (CR 31%, PR 38%) after 26 monthsNot reportedNot reportedAugust 24, 2017WM (plus rituximab)iNNOVATE (NCT02165397)5790% after 18.1 months86% at 18 months97% at 18 monthsAugust 27, 2018Naive CLL (plus obinutuzumab)iLLUMINATE (NCT02264574)5891% (CR 41%)79% at 30 months86% at 30 monthsJanuary 28, 2019Naive CLL/SLL (plus rituximab)E1912 (NCT02048813)5995.8% (CR 17.2%)89.4% at 36 months98.8% at 36 monthsApril 21, 2020Acalabrutinib (ACP-196)R/R MCLACE-LY-004 (NCT02213926)6081% (CR 40%) after 15.2 months67% at 12 months87% at 12 monthsOctober 31, 2017R/R CLL/SLLASCEND (NCT02970318)6181%Median 16.5 months94% at 12 monthsNovember 21, 2019Naive MCL (plus bendamustine-rituximab)ECHO (NCT02972840)6291% (CR 66.6%) after 49.8 monthsMedian 66.4 monthsNot reachedJanuary 17, 2025Zanubrutinib (BGB-3111)R/R MCLBGB-3111-206 (NCT03206970)6383.7% (CR 77.9%) after 35.3 months47.6% at 36 months; Median 33 months75.8% at 36 monthsNovember 14, 2019WMASPEN (NCT03053440)6421.2% after 44.4 monthsNot reachedNot reachedSeptember 1, 2021R/R MZLMAGNOLIA (NCT03846427)6568.2% after 27.4 months70.9% at 24 months85.9% at 24 monthsSeptember 15, 2021Naive CLL/SLLSEQUOIA (NCT03336333)6697.4% after 31.2 months92% at 24 months96% at 24 monthsJanuary 19, 2023R/R CLLALPINE (NCT03734016)6778.3% after 15 months94.9% at 12 months97.0% at 12 monthsDecember 22, 2023R/R FL (plus obinutuzumab)ROSEWOOD (NCT03332017)6869% (CR 39%) after 20.2 monthsMedian 28 months77% at 24 monthsMarch 7, 2024Pirtobrutinib (LOXO-305)R/R MCLBRUIN (NCT03740529)69,7057.8% (CR 20%)Median 7.4 months59.3 at 18 monthsJanuary 27, 2023CLL/SLL73.3%Median 19.6 months80.5% at 18 monthsDecember 1, 2023Tirabrutinib (ONO-4059)R/R PCNSLPROSPECT (NCT04947319)71–––FDA granted ODD (March 2023)Orelabrutinib (ICP-022)R/R MCLNCT0401420572–––FDA granted BTD (June 2021)cGVHD, chronic graft-versus-host disease; FDA, US Food and Drug Administration; R/R, relapsed/refractory; ORR, overall response rate; CR, complete response; PFS, progression-free survival; OS, overall survival; ODD, Orphan Drug Designation; BTD, Breakthrough Therapy Designation.Patients’ responses and safety profiles are discussed in the text.aWithdrawn in the United States in April 2023.39 Approved and investigational BTK inhibitors cGVHD, chronic graft-versus-host disease; FDA, US Food and Drug Administration; R/R, relapsed/refractory; ORR, overall response rate; CR, complete response; PFS, progression-free survival; OS, overall survival; ODD, Orphan Drug Designation; BTD, Breakthrough Therapy Designation. Patients’ responses and safety profiles are discussed in the text. Withdrawn in the United States in April 2023.39 A recent advancement is pirtobrutinib (Jaypirca), a highly selective noncovalent (reversible) BTKi that forms hydrogen bonding within the ATP-binding pocket of BTK independently of the C481 residue.74 Pirtobrutinib interacts with BTK through reversible hydrogen bonding and hydrophobic interactions within the kinase domain, enabling the inhibition of both wild-type BTK and mutant forms, such as C481S. This agent represents a significant step forward, particularly for patients who have developed resistance to covalent BTKi.75 In 2023, the FDA granted accelerated approval for pirtobrutinib in R/R MCL, and later that year, its indication was expanded to CLL/SLL.76 Current research is focused on understanding and overcoming acquired resistance to BTKi. In parallel, efforts are underway to develop BTKis with novel binding mechanisms. For example, the compound CGI1746 is an ATP competitive inhibitor that targets the H3 pocket within the unphosphorylated BTK structure.77 This inhibitor exhibits remarkable reversibility and demonstrates a unique binding mechanism. By suppressing both auto- and trans-phosphorylation processes essential for BTK activation, CGI1746 demonstrates over 1,000-fold selectivity for BTK compared with other kinases in the human kinome. Furthermore, preclinical studies have shown that CGI1746 is effective in animal models of inflammatory arthritis, indicating its potential therapeutic value for inflammatory disorders.22 BTKi resistance Resistance to BTKis presents a significant challenge in the management of B cell malignancies, as it compromises the long-term effectiveness of these targeted therapies. Resistance can arise through either intrinsic or acquired mechanisms.78 Intrinsic resistance refers to pre-existing molecular features that render tumor cells insensitive to BTKis independent of drug exposure. These include pre-existing mutations in genes such as TP53 and MYC, as well as constitutive activation of alternative oncogenic signaling pathways. In contrast, acquired resistance develops under the selective pressure of BTKi treatment, most classically through the emergence of BTK kinase domain mutations, particularly the C481S substitution, and gain-of-function mutations in PLCG2, both of which accumulate progressively during therapy.79 Genetic mechanisms of BTKi resistance Gene mutations contributing to primary (intrinsic)/acquired BTKi resistance Intrinsic resistance to BTKis is often driven by gene mutations that reduce drug efficacy from the outset (Figure 3). In B cell malignancies such as CLL and MCL, resistance to ibrutinib represents a significant therapeutic challenge. The most extensively characterized mechanism involves mutations at the C481 residue of the BTK gene, particularly the C481S substitution.80 This alteration modifies the ibrutinib binding site, preventing covalent attachment and allowing BTK to remain active. As a result, BTK pathway continues to promote tumor survival, ultimately leading to ibrutinib resistance. Additional substitutions at Cys481, including C481F, C481Y, C481R, C481W, C481T, and C481G, have also been implicated in resistance.79,81,82 Non-C481 mutations, such as the gatekeeper mutation T474I, L528W,78,83 and T316A (located outside the kinase domain),84 as well as less common alterations like R28S, G164D, R490H, and Q516L,85 have been observed following treatment with covalent BTKis. Several BTK mutations, including L528W, V416L, A428D, M437R, and C481F/R/Y, result in impaired kinase activity.86 In contrast, T474I retains normal kinase function and demonstrates increased autophosphorylation relative to wild-type BTK.87 Notably, co-occurrence of T474I with C481 mutations (T474I/C481S, T474M/C481S, and T474M/C481T) confers a high level of resistance to ibrutinib.88Figure 3Occurrence of mutations in BTK conferring resistance to BTKisIbrutinib primarily selects for C481 mutations, which disrupt covalent binding at the active site. Acalabrutinib and zanubrutinib utilize the same binding mechanism and are, therefore, susceptible to similar C481-driven resistance. Resistance can also arise from a broader spectrum of non-C481 mutations, including T474I and L528W. These mutations may result in either kinase-impaired or kinase-proficient phenotypes. Notably, L528W has been implicated in cross-resistance to both covalent and non-covalent BTKis. See the main text for more details. Occurrence of mutations in BTK conferring resistance to BTKis Ibrutinib primarily selects for C481 mutations, which disrupt covalent binding at the active site. Acalabrutinib and zanubrutinib utilize the same binding mechanism and are, therefore, susceptible to similar C481-driven resistance. Resistance can also arise from a broader spectrum of non-C481 mutations, including T474I and L528W. These mutations may result in either kinase-impaired or kinase-proficient phenotypes. Notably, L528W has been implicated in cross-resistance to both covalent and non-covalent BTKis. See the main text for more details. High-risk mutations in other critical genes also contribute to resistance. For example, alterations in the TP53 tumor suppressor gene can significantly impair apoptosis, a process essential for eliminating damaged or malignant cells. Similarly, mutations in the oncogene MYC can promote unchecked cellular proliferation even in the presence of BTK inhibition.13 Beyond BTK mutations, alterations in downstream components of the BCR signaling pathway also contribute to resistance. Chronic active BCR-NF-κB signaling In activated B-cell-like DLBCL (ABC DLBCL), tumor cells depend on the CBM complex for continuous NF-κB activation. Oncogenic mutations in CARD11 promote CBM aggregation, initiating persistent signaling (Figure 4).35 MALT1, a paracaspase within the CBM complex, cleaves A20 (TNFAIP3), a key negative regulator of NF-κB that is normally upregulated as part of the NF-κB response. In many ABC DLBCL tumors, A20 is frequently deleted or inactivated by mutation. By both cleaving newly produced A20 and eliminating existing A20 protein, these changes disrupt the primary negative feedback loop, allowing sustained, chronic active BCR-NF-κB signaling to drive malignant B cell survival.89Figure 4Genetic and non-genetic mechanisms of resistance to BTKis including ibrutinibResistance can arise through on-target mutations in BTK, as well as off-target mutations that alter kinase activity or reduce inhibitor-binding affinity. In addition to genetic alterations, resistance can also occur through non-genetic mechanisms, including the activation of alternative signaling pathways that sustain cell survival and proliferation despite BTK inhibition. See the main text for more details. Genetic and non-genetic mechanisms of resistance to BTKis including ibrutinib Resistance can arise through on-target mutations in BTK, as well as off-target mutations that alter kinase activity or reduce inhibitor-binding affinity. In addition to genetic alterations, resistance can also occur through non-genetic mechanisms, including the activation of alternative signaling pathways that sustain cell survival and proliferation despite BTK inhibition. See the main text for more details. BCR component mutations Gain-of-function mutations in the CD79a and CD79b ITAM motifs occur in over 20% of ABC DLBCL cases (Figure 4).35,90 These mutations impair the function of Lyn, a Src-family kinase with dual roles.91 LYN normally phosphorylates ITAMs to initiate BCR signaling and also phosphorylates the immunoreceptor tyrosine-based inhibitory motif (ITIM) of CD22 to limit signaling. Phosphorylated CD22 recruits SHP-1, a phosphatase that dephosphorylates ITAMs and terminates the signal. Mutant CD79 ITAMs disrupt the CD22-SHP-1 negative feedback loop by interfering with LYN’s ability to activate CD22. Consequently, phosphorylated ITAMs and active SYK kinase persist, resulting in abnormal BCR signaling. LYN is also required for the proper internalization of BCR after antigen engagement. When LYN is impaired, receptor internalization decreases, leading to the accumulation and clustering of mutant BCRs on the cell surface, which further enhances spontaneous signaling. By disabling both feedback regulation and receptor clearance, CD79 ITAM mutations maintain malignant B cells in a chronic active BCR signaling state, thereby promoting survival and proliferation in ABC DLBCL.92 The MyD88-TLR pathway The L265P mutation in the Toll/IL-1 receptor (TIR) of MyD88 is present in approximately 39% of ABC DLBCL cases (Figure 4).93 This substitution occurs at a critical interface, allowing MyD88 homodimerization without upstream stimulation. As a result, IRAK4 and IRAK1 are constitutively recruited, driving persistent NF-κB activation and the autocrine secretion of IL-6 and IL-10. These cytokines signal back to the same and neighboring lymphoma cells, activating their respective receptors, which then further activate the JAK-STAT and PI3K pathways, promoting cell proliferation and inhibiting apoptosis. Notably, the MyD88 L265P mutation frequently co-occurs with CD79 or CARD11 mutations. This creates convergent oncogenic signaling through the BCR-CBM-NF-κB and MyD88-IRAK-NF-κB axes. This combined signaling network establishes a robust and synergistic survival advantage in ABC DLBCL cells.94 The PI(3)K-AKT pathway The PI3K-AKT pathway is a frequent oncogenic driver in lymphomas (Figure 4).95 Under normal conditions, growth factors or external stimuli bind to receptor tyrosine kinases (RTKs) on the cell surface, activating this pathway. Activated PI3K generates PIP3, which subsequently activates AKT, a serine/threonine kinase. AKT phosphorylates downstream targets that regulate metabolism, inhibit apoptosis, and promote cell growth.96 Dysregulation of the PI3K-AKT pathway is common in lymphomas, including MCL and DLBCL.97,98 A key mechanism involves the loss or inactivation of PTEN, a tumor suppressor that dephosphorylates PIP3 to PIP2, thereby antagonizing PI3K activity. Deletion, mutation, or downregulation of PTEN results in PIP3 accumulation and constitutive AKT activation.99 The miR-17–92 cluster, encoded by the MIR17HG gene, is another well-characterized oncogenic driver.100 Amplification or overexpression of this cluster represses PTEN and PH domain and leucine-rich repeat protein phosphatase 2 (PHLPP2), both negative regulators of the PI3K-AKT axis, further sustaining AKT signaling.101 Activated AKT inhibits apoptosis by phosphorylating and inactivating pro-apoptotic proteins and also activates mTOR, which enhances protein synthesis, glucose metabolism, and cell proliferation.102 Notably, PI3K-AKT signaling cooperates with the NF-κB pathway, establishing redundant and compensatory survival circuits that can bypass BTK inhibition and contribute to resistance in B cell malignancies.103 Defects in DNA damage repair genes further contribute to treatment resistance.35 DNA damage repair is critical for preserving genomic stability. Mutations in tumor suppressor genes involved in repair compromise genomic integrity, enabling cancer cells to survive DNA damage that would otherwise induce cell death. Collectively, these defects impede the effectiveness of BTKi, especially in cases of primary resistance.104 Non-genetic mechanisms of BTKi resistance Non-genetic resistance allows B cell cancers to evade BTKis without acquiring direct genetic mutations (Figure 4). In response to therapeutic pressure, cancer cells adapt by rerouting signaling pathways and altering their metabolic programs, thereby sustaining cell survival and proliferation despite BTK inhibition. These mechanisms primarily involve activation of alternative BCR pathways, engagement of oncogenic pathways, and metabolic reprogramming.18 Activation of alternative oncogenic signaling pathways A prominent non-genetic mechanism of resistance to BTKis is the substitution of alternative survival pathways for the canonical BTK-driven signaling pathway (Figure 4). The PI3K-AKT-mTOR axis is among the most well-characterized alternative pathways.18 Under BTK inhibition, upstream signals from surface co-receptors such as CD19 and CD40 may become hyperactivated, directly stimulating PI3Kδ. As a result, AKT phosphorylation persists even in the absence of BTK activity. This compensatory activation maintains downstream mTOR signaling, supporting ongoing protein synthesis, glucose metabolism, and anti-apoptotic signaling.105 Studies have demonstrated that PI3K-AKT signaling is upregulated in ibrutinib-resistant CLL and MCL, compensating for BTK inhibition and promoting cell survival through the AKT and mTOR pathways.106 Similarly, MAPK/ERK signaling, which is typically downstream of RAS- and SRC-family kinases, can become upregulated in BTKi-resistant cells.78 Alternative kinases such as SYK and LYN activate RAS through BLNK and growth factor receptor-bound protein 2 (GRB2), leading to ERK reactivation despite BTK blockade. Increased ERK phosphorylation has been observed in ibrutinib-resistant models and is associated with sustained cyclin D1 expression and cell-cycle progression.80 Overexpression of pro-survival proteins B cell lymphoma 2 (BCL2) is a key anti-apoptotic protein.107 BCL2 blocks apoptosis by stopping mitochondrial cytochrome c release from mitochondria. BCL2 gene is located at chromosome 18q21. In follicular NHLs, the BCL2 gene is frequently translocated to the immunoglobulin heavy-chain locus at 14q32 (t(14;18)) (Figure 4),108 leading to aberrant BCL2 overexpression. This dysregulation allows malignant B cells to evade apoptosis and accumulate, promoting tumor progression. BCL2 thereby is a key therapeutic target in the pathogenesis of lymphoma.109 Similarly, B cell lymphoma 6 (BCL6) contributes to BTKi resistance in ABC DLBCL. Ibrutinib-resistant ABC DLBCL cells often exhibit significantly higher BCL6 expression.110 High levels of BCL6 inpatients have been clinically associated with poor response to BTKi therapy. As a transcriptional repressor, BCL6 suppresses genes involved in apoptosis and differentiation, including BLIMP1 (encoded by PRDM1).111 In resistant ABC DLBCL, the miR-30 family of microRNAs, which normally represses BCL6, is significantly downregulated.110 The resulting de-repression of BCL6 reinforces a pro-survival phenotype and promotes resistance. The proto-oncogene MYC encodes a transcription factor that regulates genes involved in cell growth, metabolism, and proliferation.112 MYC is frequently overexpressed in BTKi-resistant B cell malignancies.113 MYC promotes resistance by upregulating biosynthesis, energy production, and survival genes.114 MYC also sustains BCR-downstream signaling, particularly via the PI3K/AKT and NF-κB activity, and drives metabolic reprogramming, including increased oxidative phosphorylation (OXPHOS), to meet the energy demands of rapidly proliferating cells.115 Additionally, MYC enhances the expression of anti-apoptotic proteins, such as BCL-2 and MCL-1, while suppressing pro-apoptotic factors like BIM.116 These alterations collectively establish a robust pro-survival environment that contributes to therapeutic resistance.117 Metabolic adaptations Metabolic reprogramming is another key feature in BTKi resistance. One of the hallmark adaptations observed in resistant B cell malignancies is the upregulation of OXPHOS.115,118,119 This metabolic shift increases ATP production, allowing malignant B cells to sustain proliferation and survival under therapeutic pressure (Figure 4). One of the key regulators in this metabolic reprogramming is the transcription factor early growth response 1 (EGR1).119 EGR1 is induced downstream of BCR signaling via the MAPK and calcium pathways120 and also through JAK1 activation, which promotes gene expression via H3Y41 phosphorylation in DLBCL cells.121 Once expressed, it regulates genes that control critical cellular programs, including ZFP36L2, BCL2, TP53, PDP1, and MYC, as well as target genes of MYC and the E2 transcription factor (E2F) pathway.122,123 In the context of BTKi resistance, it has been demonstrated that EGR1 is significantly overexpressed in ABC DLBCL and MCL cells and remains active even in the absence of upstream BTK activity, suggesting a BTK-independent survival mechanism.119 Mechanistically, EGR1 activates the transcription of pyruvate dehydrogenase phosphatase 1 (PDP1), a phosphatase that dephosphorylates and activates the pyruvate dehydrogenase (PDH) complex.124 This activation enhances the conversion of pyruvate into acetyl-CoA, fueling the tricarboxylic acid cycle and promoting OXPHOS. The resulting metabolic reprogramming supports sustained proliferation and drug resistance.119 In parallel, DNA methyltransferase 3A (DNMT3A) plays a pivotal role in metabolic adaptation through a methylation-independent mechanism.115 Although classically recognized as an epigenetic regulator that methylates promoter and enhancer regions, often in cooperation with DNMT3B, DNMT3A also functions as a transcription co-activator in BTKi-resistant cells.125 Zhang et al.118 and Hoang et al.115 demonstrated that DNMT3A expression is upregulated in ibrutinib-resistant MCL cells. Rather than acting through classical DNA methylation, DNMT3A forms a transcriptional activating complex with myocyte enhancer factor 2B (MEF2B) and MYC to regulate the expression of genes involved in mitochondrial biogenesis and respiration. This complex upregulates the genes involved in mitochondrial biogenesis and respiration, such as mitochondrial transcription factor A (TFAM, a key regulator of mitochondrial DNA replication) and cytochrome c oxidase subunit 6C (COX6C, a component of the electron transport chain).115 As a result, DNMT3A enhances mitochondrial mass, membrane potential, and ATP production, reinforcing OXPHOS dependency in resistant cells. Importantly, even catalytically inactive mutants of DNMT3A retain the ability to enhance OXPHOS via this transcriptional mechanism, highlighting a non-canonical, methylation-independent function in regulating metabolic fitness. Signaling of immune cells in the tumor microenvironment upon BTKi inhibition Tumor-associated macrophages (TAMs) are key components of the tumor microenvironment (TME) and have been implicated in the development of drug resistance.126 TAMs are broadly classified into two polarized states: M1 and M2. M1 macrophages express high levels of major histocompatibility complex class II (MHC-II) molecules and secrete pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α).127 In contrast, M2 macrophages exhibit reduced phagocytosis and antigen presentation. Instead, M2 macrophages secrete anti-inflammatory mediators, such as transforming growth factor β (TGF-β), which suppress T cell function, as well as chemokines like C-C motif chemokine ligand 24 (CCL24), which support tumor proliferation and therapeutic resistance.128 In patients exhibiting ibrutinib resistance, M2-like macrophages release CXCL5 and IL-8. These ligands act on CXCR2 on MCL cells. The signal activates the PI3K/AKT, p38, and STAT3 pathways, thereby promoting survival and conferring ibrutinib resistance.129 Interleukin-4 (IL-4) is another cytokine that also contributes to the resistant phenotype. It is produced by activated Th2 cells, mast cells, and basophils.130 In CLL patients, treated with ibrutinib, levels of most pro-survival cytokines in the plasma decrease; however, IL-4 and IL-6 often persist. IL-4 binds IL-4R on the leukemia cells, activating the JAK1/3-STAT6 pathway and downstream PI3K/AKT and NF-κB signaling, despite BTK blockade.131,132 These signaling cascades maintain the expression of anti-apoptotic proteins such as MCL-1 and BCL-xL, thereby rescuing leukemia cells from ibrutinib-induced cytotoxicity. Beyond cytokine-mediated signaling, the chemokine axis involving chemokine receptor 4 (CXCR4) and its ligand chemokine ligand 12 (CXCL12) plays a central role in anchoring malignant B cells within protective bone marrow and lymphoid tissue niches. CXCL12 is constitutively secreted by bone marrow stromal cells and lymph node stromal fibroblasts, acting as a potent chemoattractant for CLL and MCL cells that express high levels of CXCR4.133 The binding of CXCL12 to CXCR4 on CLL and MCL cells triggers downstream activation of PI3K/AKT, ERK, and NF-κB signaling pathways that collectively promote cell survival and proliferation independent of BTK activity.18 This niche-based protection also stimulates upregulation of BCL-2 and MCL-1, further preventing malignant B cells from apoptosis.13 Ibrutinib treatment disrupts CXCR4-mediated retention of malignant B cells in the bone marrow and impairs integrin-mediated adhesion by inhibiting BTK-dependent downstream signaling; cells are, therefore, mobilized into the peripheral blood and result in early lymphocytosis.134 However, ibrutinib does not fully abrogate CXCR4-driven survival signaling. As a result, the subpopulation of tumor cells retained within these stromal microenvironments can evade BTKi-induced apoptosis through sustained CXCL12/CXCR4 signaling.135 In WM, gain-of-function CXCR4 WHIM-like mutations (e.g., S338X) prevent CXCR4 desensitization, thereby further enhancing microenvironmental retention. This prolongs downstream AKT and ERK activation and contributes to ibrutinib resistance.136 Adhesion molecules represent another critical component of TME mediated BTKi resistance. In CLL and MCL cells, the β1 integrin VLA-4 (CD49d/CD29 heterodimer) mediates adhesion to fibronectin and VCAM-1 on bone marrow stromal cells and follicular dendritic cells and activates PI3K and NF-κB survival signaling pathways in a BTK-independent manner.137 Although ibrutinib can rapidly abrogate VLA-4-dependent fibronectin adhesion in CLL patients (median reduction 98% on day 28),138 during prolonged treatment with ibrutinib, VLA-4 can be reactivated in CLL cells via the PI3K signaling pathway in a BTK-independent manner, and high CD49d expression (a prognostic marker for CLL) is associated with reduced ibrutinib-induced lymphocytosis and progression-free survival (PFS). In MCL, interaction between stromal cell and VLA-4 protects tumor cells from ibrutinib-induced cell death, whereas co-targeting VLA-4 or combining ibrutinib with PI3K p110α inhibitors can restore drug sensitivity in preclinical models.18 Monocyte-derived nurse-like cells (NLCs), which differentiate from circulating monocytes within the CLL and MCL TME, represent another key cellular component supporting tumor survival. In CLL, NLCs protect leukemic cells from spontaneous apoptosis through the secretion of CXCL12/SDF-1α.133 In addition, NLCs produce B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which activate NF-κB1/NF-κB2 signaling and promote the upregulation of MCL-1 expression.139 Notably, at clinically achievable concentrations of ibrutinib (0.1–0.4 μM), the anti-apoptotic protection mediated by NLCs is maintained in both treatment-naive and ibrutinib-treated patient-derived cells. This observation indicates that the NLC-mediated pro-survival effect is independent of BTK activity and persist throughout the therapy.140 The protective microenvironment of the bone marrow and lymphoid tissues, maintained through CXCL12/CXCR4 signaling, VLA-4-mediated adhesion, and interactions with NLCs, collectively enables resistant tumor cells to survive and acquire resistant mutations. In the peripheral blood, CXCR4lowCD5high CLL cells represent a proliferative population that has recently exited from lymph nodes. Upon clinical progression during treatment with ibrutinib, this CXCR4lowCD5high proliferative subset re-emerges and is enriched for BTK and PLCγ2 mutations.141 Notably, using high-sensitivity next-generation sequencing (NGS), resistance-associated mutations in BTK and PLCγ2 can be detected up to 15 months prior to clinical progression.79 This indicates that subclonal selection occurs early and is driven by selective expansion within protected tissue microenvironments. Collectively, these findings demonstrate that the TME not only provides protection but also actively promotes the selective expansion of BTKi-resistant clones during therapy. Cancer stem cells MCL-initiating cells (MCL-ICs) form a rare, quiescent subpopulation within MCL, characterized by a CD45+ CD19- phenotype and stem cell-like properties.142 MCL-ICs bypass BCR-BTK signaling for survival by upregulating Wnt ligands (Wnt3 and Wnt7b) and Frizzled receptors (FZD1, FZD5, FZD6, and FZD9), leading to β-catenin accumulation and induction of Wnt target genes such as ID2 and TCF4.143 These transcriptional changes support self-renewal and survival under BTK blockade. Additionally, MCL-ICs overexpress ATP-binding cassette (ABC) transporters, including ABCC3 and ABCC6, which actively export ibrutinib out of the cell, thereby preventing it from reaching cytotoxic intracellular concentrations. Together, these features enable MCL-ICs to persist during ibrutinib therapy and potentially regenerate the tumor upon treatment cessation. The resistance mechanisms described above exhibit substantial heterogeneity across different subtypes of B cell malignancies, which has important implications for clinical decision-making. In CLL, acquired on-target mutations in BTK (predominantly C481S) and gain-of-function mutations in PLCG2 account for approximately 80% of acquired resistance to covalent BTKis.144 These genetic mechanisms are, therefore, the most clinically actionable in CLL, driving the use of noncovalent BTKis such as pirtobrutinib and BTK-PROTACs such as NX-2127 and BGB-16673, which target both wild-type and mutant BTK.69,145 In addition, the CXCR4/CXCL12 stromal axis and NLC-mediated survival represent clinically relevant microenvironmental mechanisms in CLL, forming a protective niche that preserves residual disease and facilitates clonal evolution.133,140,141 In MCL, resistance more commonly involves non-genetic mechanisms. Activation of the PI3K-AKT-mTOR pathway and metabolic reprogramming toward OXPHOS are well characterized and the most clinically relevant resistance mechanisms. There are supportive preclinical data of the combination treatment of ibrutinib with OXPHOS inhibitors (e.g., metformin and IACS-010759) and glutaminase (GLS) inhibitors (e.g., telaglenastat).118,119,146 Notably, bispecific antibodies (e.g., glofitamab) and chimeric antigen receptor T (CAR T) cell therapies demonstrate the most robust clinical efficacy in BTKi-refractory MCL because they engage cytotoxic immune mechanisms that are entirely independent of BCR/BTK signaling.147,148 In WM, the co-occurrence of MYD88 L265P and CXCR4 WHIM-like mutations defines a particularly drug-resistant genotype. CXCR4 WHIM mutations impair receptor internalization, thereby sustaining downstream PI3K/AKT and ERK signaling and attenuating the efficacy of ibrutinib.136 This mechanism can be therapeutically targeted using CXCR4 antagonists such as plerixafor. Non-covalent BTKis and PROTAC degraders also represent promising strategies for MYD88/CXCR4 double-mutant WM. Additionally, BTK degraders such as NX-5948, which can penetrate the blood-brain barrier, hold particular therapeutic potential.149 In ABC-DLBCL, resistance is predominantly driven by genetic mechanisms that constitutively activate the BCR-NF-κB axis. Key contributing mutations include oncogenic alterations in CARD11, ITAM mutations in CD79A/B, and MYD88.35 These alterations cooperate to maintain persistent downstream signaling, making the BTKi monotherapy ineffective in DLBCL patient populations.93 Nevertheless, these mutations provide a clear rationale for targeted combination strategies. Dual inhibition of BTK and PI3K using ibrutinib and copanlisib has demonstrated selective activity particularly in CD79B/MYD88 double-mutant ABC DLBCL with enhanced efficacy.150 In addition, co-targeting BTK and MALT1 further increases cytotoxic effects in CD79-mutant population, supporting the therapeutic value of disrupting multiple nodes within the same signaling network.151 Strategies to overcome acquired BTKi resistance Second-generation covalent BTKis Ibrutinib is a covalent BTKi that binds irreversibly to the C481 residue.6 Resistance frequently develops through BTK C481 mutations, particularly the C481S substitution, which prevents covalent binding. In addition, activating mutations in PLCG2, a downstream effector in the BCR pathway, can also bypass BTK signaling. Both mechanisms contribute to cross-resistance among all covalent BTKis (Figure 3).79 Second-generation covalent inhibitors, including acalabrutinib, zanubrutinib, tirabrutinib, and orelabrutinib, utilize the same irreversible, C481-dependent mechanism, but are engineered for greater selectivity, thereby reducing off-target effects such as EGFR or ITK inhibition. This improved selectivity results in a lower incidence of adverse events, including atrial fibrillation and bleeding, while maintaining clinical efficacy (Table 2). In the ELEVATE-RR trial, acalabrutinib demonstrated non-inferior PFS and a significantly lower incidence of atrial fibrillation (∼9.4% vs. 16.0%).169,170 In the phase 3 ALPINE study, zanubrutinib achieved superior PFS and a reduced rate of atrial fibrillation.171,172 Tirabrutinib showed high selectivity and good safety across B cell malignancies.173 Tirabrutinib exhibited high kinase selectivity and a favorable safety profile across B cell malignancies.73 Orelabrutinib demonstrated promising efficacy and tolerability in R/R MCL.174Table 2Investigational treatment strategies for B cell malignanciesStrategiesRegimenIndicationORRPFSOSTrial ID/studyBTK-PROTACsNX-2127CLL41%Non-disclosedNCT04830137152NX-594843%NCT05131022153BGB-1667370%NCT05006716154AC676R/R BCMNon-disclosedNCT05780034155BTK + P13KIbrutinib + copanlisibR/R MCL87.5% (CR 50%)Median 7.7 monthsNot reportedNCT03877055156BTK + BCL2Ibrutinib + venetoclaxR/R MCL82% (CR 54%)Median 22.1 months66% at 24 monthsSYMPATICO (NCT03112174)157Pirtobrutinib + venetoclaxR/R CLL96%Median 22.1 months87.5% at 24 monthsBRUIN (NCT03740529)158BTK + MALTPirtobrutinib + safimaltibR/R MCL–––Jiang et al.,159 2023Ibrutinib + S-MepazineABC-DLBCL–––Nagel et al.,151 205BTK + SYKIbrutinib + masitinibDLBCL–––Battistello et al.,160 2018Luxeptinib (CG-806)MCL–––Thieme et al.,161 2022BTK + MYCIbrutinib + JQ1MCL–––Sun et al.,162 2015BTK + OXPHOSIbrutinib + Metformin/IM156MCL/DLBCL–––Liu et al.,119 2023Ibrutinib + IACS-010759MCL–––Zhang et al.,118 2019Ibrutinib + CB-839MCL–––Li et al.,146 2023Ibrutinib + decitabineMCL–––Hoang et al.,115 2024bsAbGlofitamab (CD20 × CD3)MCL85% (CR 78.3%)Median 16.8 months72.7% at 15 monthsNCT03075696163Epcoritamab (CD20 × CD3)CLL61% (CR 39%)Median 12.8 months65% at 15 monthsEPCORE (NCT04623541)164Odronextamab (CD20×CD3)R/R DLBCL52% (CR 31.5%)Median 4.4 monthsMedian 9.5 monthsELM-2 (NCT03888105)165Blinatumomab (CD19×CD3)CLL/DLBCL43% (19%)Median 3.7 monthsMedian 5 monthsNCT01741792166CAR TIbrutinib + CD19 CAR TR/R MCL80%75% at 12 months100% at 12 monthsTARMAC (NCT04234061)148Ibrutinib + huCART-19CLL83%70% at 48 months84% at 48 monthsNCT02640209167Acalabrutinib + CD19 CAR TR/R BCL93% (CR 71%)53% at 13.8 months73% at 13.8 monthsNCT04257578168OXPHOS, oxidative phosphorylation; bsAb, bispecific antibodies; CAR T, chimeric antigen receptor T cell.Patients’ responses and safety profiles are discussed in the main text. Table 2Investigational treatment strategies for B cell malignanciesStrategiesRegimenIndicationORRPFSOSTrial ID/studyBTK-PROTACsNX-2127CLL41%Non-disclosedNCT04830137152NX-594843%NCT05131022153BGB-1667370%NCT05006716154AC676R/R BCMNon-disclosedNCT05780034155BTK + P13KIbrutinib + copanlisibR/R MCL87.5% (CR 50%)Median 7.7 monthsNot reportedNCT03877055156BTK + BCL2Ibrutinib + venetoclaxR/R MCL82% (CR 54%)Median 22.1 months66% at 24 monthsSYMPATICO (NCT03112174)157Pirtobrutinib + venetoclaxR/R CLL96%Median 22.1 months87.5% at 24 monthsBRUIN (NCT03740529)158BTK + MALTPirtobrutinib + safimaltibR/R MCL–––Jiang et al.,159 2023Ibrutinib + S-MepazineABC-DLBCL–––Nagel et al.,151 205BTK + SYKIbrutinib + masitinibDLBCL–––Battistello et al.,160 2018Luxeptinib (CG-806)MCL–––Thieme et al.,161 2022BTK + MYCIbrutinib + JQ1MCL–––Sun et al.,162 2015BTK + OXPHOSIbrutinib + Metformin/IM156MCL/DLBCL–––Liu et al.,119 2023Ibrutinib + IACS-010759MCL–––Zhang et al.,118 2019Ibrutinib + CB-839MCL–––Li et al.,146 2023Ibrutinib + decitabineMCL–––Hoang et al.,115 2024bsAbGlofitamab (CD20 × CD3)MCL85% (CR 78.3%)Median 16.8 months72.7% at 15 monthsNCT03075696163Epcoritamab (CD20 × CD3)CLL61% (CR 39%)Median 12.8 months65% at 15 monthsEPCORE (NCT04623541)164Odronextamab (CD20×CD3)R/R DLBCL52% (CR 31.5%)Median 4.4 monthsMedian 9.5 monthsELM-2 (NCT03888105)165Blinatumomab (CD19×CD3)CLL/DLBCL43% (19%)Median 3.7 monthsMedian 5 monthsNCT01741792166CAR TIbrutinib + CD19 CAR TR/R MCL80%75% at 12 months100% at 12 monthsTARMAC (NCT04234061)148Ibrutinib + huCART-19CLL83%70% at 48 months84% at 48 monthsNCT02640209167Acalabrutinib + CD19 CAR TR/R BCL93% (CR 71%)53% at 13.8 months73% at 13.8 monthsNCT04257578168OXPHOS, oxidative phosphorylation; bsAb, bispecific antibodies; CAR T, chimeric antigen receptor T cell.Patients’ responses and safety profiles are discussed in the main text. Investigational treatment strategies for B cell malignancies OXPHOS, oxidative phosphorylation; bsAb, bispecific antibodies; CAR T, chimeric antigen receptor T cell. Patients’ responses and safety profiles are discussed in the main text. Third-generation non-covalent BTKis Third-generation BTKis pirtobrutinib (LOXO-305, Jaypirca) and nemtabrutinib (MK-1026 or ARQ-531) are reversible, non-covalent inhibitors. Unlike earlier generations, these inhibitors bind reversibly and can inhibit both wild-type and C481 mutant BTK, thus overcoming the primary mechanism of resistance to ibrutinib (Table 2). In the BRUIN trial, pirtobrutinib demonstrated substantial activity in patients previously treated with covalent BTKis and exhibited a favorable safety profile.175,176 Nemtabrutinib binds BTK through hydrogen bonds with E475 and Y476, and preclinical and clinical studies have confirmed its activity in R/R B cell malignancies.177 Although next-generation BTKis provide significant therapeutic benefits, their use frequently leads to the emergence of novel BTK resistance variants (Figure 3). The most common mutations occur at the T474 residue (T474I/F/S/T/L)86 and L528W,78 both of which confer cross-resistance to second-generation BTKis like acalabrutinib and zanubrutinib. Resistance to the non-covalent BTKi pirtobrutinib has been linked to mutations such as V416L, A428D, M437R, T474I, and L528W.178 Substitutions at the C481 residue remain prevalent among resistant variants to second-generation covalent BTKis. For instance, BTK C481S/R mutations have been identified in patients resistant to zanubrutinib179 and C481S/Y/R have been observed in acalabrutinib resistance.180 However, C481 substitutions are rarely detected in pirtobrutinib resistance. Despite therapeutic advances, PLCγ2-driven resistance remains a significant challenge for both covalent and non-covalent BTKis.181 Variants in PLCG2, such as R665W, L845F, and S707Y, within the autoinhibitory domain, confer gain-of-function properties.182 These mutations uncouple PLCγ2 from BTK, enabling sustained IP3/DAG production, calcium flux, and downstream MAPK/NF-κB signaling despite BTK inhibition. In ibrutinib-resistant CLL, such intact downstream signaling is commonly observed. Mutations in BTK and/or PLCG2 collectively account for approximately 80% of the acquired resistance to covalent BTKis.144 Ultra-deep sequencing has shown that resistant BTK and PLCG2 PLCγ2 clones can emerge months prior to clinical progression.79 A recent meta-analysis estimated the overall pooled incidence of PLCG2 mutations at approximately 11% (13% in ibrutinib-treated patients and 9% in those treated with acalabrutinib or zanubrutinib).183 Notably, PLCγ2-mediated escape mechanisms have also been observed during treatment with third-generation noncovalent BTKis, underscoring that inhibitors not dependent on the C481 residue can still be circumvented via downstream bypass pathways.178 BTK-PROTACs BTK-PROTACs (proteolysis-targeting chimeras) are heterobifunctional molecules that induce selective degradation of BTK (Table 2).184 These agents link BTK with an E3 ligase, most commonly cereblon (CRBN), facilitating the formation of a ternary complex that leads to BTK ubiquitination and subsequent proteasomal degradation.185 In contrast to conventional BTKis that bock enzymatic activity, PROTACs eliminate the BTK protein entirely, including wild-type and drug-resistant variants such as C481S.186,187 Importantly, BTK-PROTACs can also degrade kinase-impaired or catalytically inactive BTK mutants, thereby silencing non-catalytic scaffold functions of BTK.87 This provides a more comprehensive suppression of BCR signaling compared with conventional BTKis. Preclinical compounds such as MT-802 and UBX-382 have degraded multiple resistant mutants, including V416L, T474I, and L528W, thereby resulting in downstream signaling inhibition.185 Initial clinical trials show that BTK degraders exhibit promising activity in heavily pretreated patients with B cell malignancies (Table 2). NX-2127, the first BTK degrader to enter clinical testing, is a dual-function agent targeting both BTK and cereblon substrates IKZF1/3, thereby combining BTK degradation with immunomodulatory effects similar to immunomodulatory drugs.188 In a phase 1 trial (NCT04830137) involving patients with R/R B cell malignancies, NX-2127 achieved an overall response rate (ORR) of approximately 41%, with a manageable safety profile.189 NX-5948, another oral BTK degrader, has brain-penetrant properties and demonstrated objective responses in 7 of 9 (77.8%) patients with WM. It has received FDA fast-track designation for R/R CLL.190 Notably, it also provided the first clinical evidence of central nervous system activity for a BTK degrader.149 BGB-16673 has shown early clinical efficacy and a favorable safety profile in BTK-resistant settings. In a cohort of R/R CLL/SLL patients, it achieved objective responses in 72% (31/43), including an 88% ORR at the 200 mg dose, with two patients achieving complete responses (CRs).145 AC676, another orally bioavailable BTK degrader currently being evaluated in a phase 1 dose-escalation study (NCT05780034), demonstrated activity even in cell lines harboring gain-of-function PLCG2 mutations.155 Collectively, BTK-PROTACs represent a promising strategy to overcome both on-target and downstream resistance mechanisms to BTK inhibition. However, emerging resistance to degraders has also been reported, including mutations such as BTK A428D or alterations in E3 ligase pathways. These findings highlight the potential need for combination therapies to enhance durability and overcome resistance. Co-targeting oncogenic signaling B cells can circumvent BTK inhibition by activating alternative signaling pathways, including the PI3K-AKT-mTOR pathway, SRC-family kinases such as LYN, and MYC-driven transcription.95,191 In MCL, the microenvironment and kinome reprogramming sustain PI3K-AKT-mTOR signaling after BTK inhibition. Concurrent inhibition of both BTK and PI3K-AKT-mTOR pathways restores drug sensitivity in patient samples and patient-derived xenograft (PDX) models, demonstrating the therapeutic potential of dual pathway blockade.192 Co-targeting strategies are, therefore, designed to suppress both BTK and these compensatory signaling circuits (Table 2). PI3K is a promising downstream target for combination therapy. Dual inhibition with ibrutinib and copanlisib, a PI3Kα/δ inhibitor, effectively suppressed NF-κB and AKT signaling in CD79B/MyD88-mutant ABC DLBCL, leading to CRs in resistant models.150 Early-phase clinical trials of copanlisib combined with ibrutinib in R/R lymphoma (NCT03877055) have demonstrated feasibility, although PI3K-associated toxicities remain a significant concern.156 Dual targeting of BTK and BCL-2 represents another effective therapeutic strategy. In R/R MCL, the combination of ibrutinib and venetoclax has demonstrated synergistic activity by concurrently inhibiting BCR signaling and mitochondrial anti-apoptotic mechanisms. In a phase 1/2 trial (NCT02471391), this regimen achieved an ORR of 71%, with CRs in 63% of patients and a median duration of response (DOR) of 18.9 months.157 In R/R CLL, the combination of pirtobrutinib and venetoclax is under investigation as a chemotherapy-free, fully oral regimen. Preliminary data from the BRUIN study (NCT03740529) show deep and durable responses, including a high rate of undetectable minimal residual disease (MRD) in patients with high-risk molecular features.158 MALT1 has emerged as a rational co-target for overcoming resistance. Overexpression of MALT1 has been observed in ibrutinib-resistant MCL.159 Pharmacologic inhibition of MALT1 with safimaltib suppressed NF-κB and PI3K-AKT signaling and reduced proliferation in resistant cell lines and patient samples. The combination of pirtobrutinib and safimaltib effectively inhibited NF-κB and PI3K pathways and decreased tumor burden in both cell lines and PDX models.159 Similar findings have been reported in ABC DLBCL, where dual BTK + MALT1 inhibition enhanced cytotoxicity, particularly in CD79-mutant backgrounds.151 SRC-family kinases have been investigated as co-targets to address proximal signaling rewiring. In ibrutinib-resistant DLBCL, dual inhibition with ibrutinib and masitinib, a pan-SRC inhibitor, suppressed global tyrosine phosphorylation and MYC upregulation.160 Similarly, the dual BTK/SYK inhibitor luxeptinib (CG-806) effectively disrupted BCR signaling, reduced MCL-1 and BCL-xL expression, and overcame stromal-mediated protection in ibrutinib-resistant MCL cells and primary samples. These results support SRC/SYK-family co-inhibition as a viable therapeutic strategy.161 Targeting MYC provides an additional therapeutic layer. In both sensitive and resistant MCL models, the combination of the BET bromodomain inhibitor JQ1 with ibrutinib suppressed phosphorylated BTK, total BTK, phosphorylated PLCγ2, and nuclear RelA. In xenograft mouse models, this combination significantly prolonged survival, confirming in vivo synergy.162 Co-targeting metabolic pathways such as using OXPHOS inhibitors Ibrutinib-resistant B cell lymphomas frequently switch to mitochondrial metabolism, relying on OXPHOS and, in some cases, glutaminolysis.146 Mechanistically, resistance is driven by the EGR1/PDP1 axis, which activates pyruvate dehydrogenase and boosts OXPHOS, and the DNMT3A/MYC program transcriptionally drives MYC targets and OXPHOS independent of DNA methylation.115,119 Functionally, co-targeting these metabolic programs restores BTKi sensitivity in preclinical models. In both DLBCL and MCL, the addition of metformin or the clinical OXPHOS inhibitor IM156 to ibrutinib produced synergistic effects in multiple cell lines and primary MCL samples. In ibrutinib-resistant xenograft models, the combination of ibrutinib and metformin reduced tumor growth and increased apoptosis, resulting in significant reductions in tumor volume compared with either monotherapy, without causing weight loss.119 In MCL, the upregulation of OXPHOS and glutaminolysis is a hallmark of ibrutinib resistance. The complex-I inhibitor IACS-010759 demonstrated potent inhibitory activity in ibrutinib-resistant patient-derived models both in vitro and in PDXs.118 Combining ibrutinib with IACS-010759 reduced proliferation from 25% to 6%.193 Additionally, resistant MCL cells overexpress GLS and become glutamine dependent. The GLS inhibitor telaglenastat (CB-839) synergized with ibrutinib, increasing apoptosis and improving tumor control in PDXs.146 Hoang et al. identified DNMT3A driven, MYC-linked OXPHOS as a resistance mechanism and showed that low-dose decitabine suppressed tumor growth both in vitro and in an MCL PDX model, while sensitizing cells to ibrutinib.115 In CLL, OXPHOS inhibition alone induced limited cell death; however, combined inhibition of glycolysis using 2-deoxy-D-glucose resulted in significantly enhanced cytotoxicity.194 Collectively, these findings support the blockade of OXPHOS and glutaminolysis as a clinically viable strategy and highlight metabolic co-targeting as a viable approach to overcome acquired BTKi resistance. Combination with bispecific antibodies Although mutations in the BCR signaling pathway can compromise the efficacy of kinase inhibitors, they do not impede T-cell-mediated cytotoxicity. Bispecific antibodies (bsAbs) represent a promising therapeutic strategy by simultaneously engaging CD3 on patient T cells and tumor-associated antigens such as CD20 or CD19 (Table 2).195 This dual engagement triggers potent T-cell-mediated cytotoxicity that is independent of BTK signaling, making bsAbs particularly attractive in both covalent and non-covalent BTKi-exposed disease settings.196 Glofitamab, a CD20×CD3 bsAb, has demonstrated robust clinical activity in R/R MCL. In the phase 1/2 NP30179 study, glofitamab achieved an ORR of 78%. In BTKi-pretreated MCL patients (NCT03075696), the ORR was 74%, with a CR rate of 71%. The median PFS was 8.6 months, and the median DOR was 12.6 months.147,163 Epcoritamab, a subcutaneously administered CD20×CD3 bsAb, has also shown promising activity in BTKi-refractory CLL, with an ORR of 61%, a CR rate of 39%, and a median PFS of 12.8 months.164 Odronextamab, another CD20×CD3 bsAb engineered with an extended serum half-life, has shown efficacy in R/R DLBCL patients involved in the ELM-2 study (NCT03888105). Odronextamab monotherapy, achieved an ORR of 52% and a CR rate of 31%. Responses were durable with a DOR of 10.2 months and a median PFS of 4.8 months. Importantly, responses were observed across both CAR-T-naive and CAR-T-exposed subgroups (ORR 48% in post-CAR T patients). The safety profile was manageable, with most cytokine release syndrome (CRS) events being low grade.165 Beyond CD20 targeting, CD19×CD3 bsAbs offer additional therapeutic options. Blinatumomab (AMG103 or MT103), the first approved CD19×CD3 bsAb, has shown promising antitumor activity in both preclinical and clinical settings. In vitro, it induced autologous T cell killing of CLL cells at very low effector-to-target ratios.197 Clinically, blinatumomab monotherapy in R/R B-NHL achieved ORRs of 43%–69% and CR rates of 19%–22%, with median overall survival (OS) ranging from 4.6 to 7.7 years.166,198 Notably, BTKis such as ibrutinib may enhance bsAb efficacy by reversing T cell exhaustion. Preclinical and translational studies have shown that ibrutinib can reinvigorate dysfunctional CLL T cells, thereby augmenting bsAb-mediated cytotoxicity.199,200 However, this effect may be context and schedule dependent, as other studies have reported impaired bsAb activity in the presence of concurrent ibrutinib treatment.201 Combination with chimeric antigen receptor T cells CAR T cells are autologous T cells engineered to express chimeric antigen receptors that typically target CD19, enabling cytotoxic killing of B cell tumors independent of BCR/BTK signaling (Table 2).202 This BTK independence makes CAR T cell therapy an attractive option for patients with BTK-resistant disease.202 Beyond BTK inhibition, ibrutinib has inhibited T cell kinase (ITK), shifting CD4+ T cells toward a Th1 phenotype and improving T cell fitness.203 Preclinical studies have demonstrated that ibrutinib exposure enhances CAR T expansion, reduces exhaustion markers (PD-1/TIM-3/LAG-3), and improves antitumor activity in CLL patient-derived models.204 Clinical data support the rationale for combining BTKis with CAR T cells in R/R B cell malignancies. In MCL, where relapse following BTKi treatment is common, the phase 2 TARMAC trial (NCT04234061) evaluated time-limited ibrutinib in combination with CTL019 (CD19 CAR T). Among 20 patients previously treated with or refractory to BTKis, after a median follow-up of 13 months, the 12-month PFS and OS were 75% and 100%, respectively. At 4 months post-treatment, 70% of patients achieved MRD negativity, indicating deep responses.148 In CLL, the addition of CAR T therapy to ongoing BTKi treatment has demonstrated enhanced efficacy. In a trial of humanized CAR T 19 combined with ibrutinib, patients who had not achieved a CR on BTKi monotherapy experienced a CR rate of 44% at 3 months post-CAR T infusion. At 12 months, undetectable MRD was achieved in 72% of patients. Long-term outcomes included 48-month OS and PFS rates of 84% and 70%, respectively. CRS was generally low grade.167 Second-generation BTKi combinations are also under investigation. In a study of R/R BCL (NCT04257578), acalabrutinib was given as both bridging and concurrent therapy with axi-cel (CD19 CAR T). Among 17 treated patients, the ORR was 76% and CR rate was 65%, with 61% of patients remaining in CR at 12 months.168 These data collectively support the strategy of combining BTKis with CAR T therapy, both in BTKi-naive and BTKi-exposed patients, to enhance T cell efficacy, deepen responses, and potentially prolong survival. Conclusion and future directions BTKis have reshaped the treatment landscape for B cell malignancies. However, acquired resistance and outcomes following BTKi therapy remain major clinical challenges. Recent advances in next-generation inhibitors, metabolic targeting, and immune-based strategies offer promising avenues to overcome resistance and restore therapeutic efficacy. Several of these combination approaches have demonstrated durable responses in BTKi-refractory patients, setting the stage for rational, biomarker-driven trials. As the field evolves, there is a growing shift toward personalized treatment strategies tailored to the molecular and cellular context of the disease. NGS and multi-omics approaches, encompassing genomics, transcriptomics, proteomics, and metabolomics, will play a critical role in identifying both genetic and non-genetic mechanisms driving R/R disease following BTKi therapy. Future decisions regarding treatment sequencing and combinations will increasingly be guided by tumor genetics, signaling rewiring, metabolic dependencies, and microenvironmental cues, rather than relying on fixed lines of therapy. Acknowledgments We appreciate the BioRender (https://www.biorender.com) for help with figure production during the preparation of this manuscript. This work was supported by the 10.13039/100000002National Institutes of Health and 10.13039/100000054National Cancer Institute (NIH/NCI), United States, with the R01 grant CA266354 and the UW Fall Research Competition Award (L.R.). Author contributions Q.N. and L.R. conceived and designed the review. Q.N. collected and analyzed the references and wrote the manuscript. L.R. reviewed and edited the manuscript. Declaration of interests The authors have declared no conflict of interests in this work.